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Fructose, weight gain, and the insulin resistance syndrome1–3
Sharon S Elliott, Nancy L Keim, Judith S Stern, Karen Teff, and Peter J Havel
ABSTRACT
This review explores whether fructose consumption might be a
contributing factor to the development of obesity and the accom-
panying metabolic abnormalities observed in the insulin resist-
ance syndrome. The per capita disappearance data for fructose
from the combined consumption of sucrose and high-fructose corn
syrup have increased by 26%, from 64 g/d in 1970 to 81 g/d in
1997. Both plasma insulin and leptin act in the central nervous
system in the long-term regulation of energy homeostasis.
Because fructose does not stimulate insulin secretion from pan-
creatic  cells, the consumption of foods and beverages contain-
ing fructose produces smaller postprandial insulin excursions than
does consumption of glucose-containing carbohydrate. Because
leptin production is regulated by insulin responses to meals, fruc-
tose consumption also reduces circulating leptin concentrations.
The combined effects of lowered circulating leptin and insulin in
individuals who consume diets that are high in dietary fructose
could therefore increase the likelihood of weight gain and its asso-
ciated metabolic sequelae. In addition, fructose, compared with
glucose, is preferentially metabolized to lipid in the liver. Fruc-
tose consumption induces insulin resistance, impaired glucose tol-
erance, hyperinsulinemia, hypertriacylglycerolemia, and hyper-
tension in animal models. The data in humans are less clear.
Although there are existing data on the metabolic and endocrine
effects of dietary fructose that suggest that increased consumption
of fructose may be detrimental in terms of body weight and adi-
posity and the metabolic indexes associated with the insulin resist-
ance syndrome, much more research is needed to fully understand
the metabolic effect of dietary fructose in humans. Am J Clin
Nutr 2002;76:911–22.
KEY WORDS Fructose, leptin, weight gain, insulin
resistance, triacylglycerol, hypertension, obesity, review
INTRODUCTION
The prevalence of obesity in the United States and worldwide
is increasing (1, 2). More than one-half of US men and women
aged ≥ 20 y are considered overweight [ie, a body mass index
(BMI; in kg/m2) ≥ 25], and nearly one-fourth are clinically obese
(BMI ≥ 30) (3, 4). Although extreme obesity has received the most
attention in the clinical setting, most obesity in the population can
be described as moderate to marked. However, even moderate obe-
sity can contribute to chronic metabolic abnormalities character-
istic of the insulin resistance syndrome, such as dyslipidemia,
hypertension, insulin resistance, and glucose intolerance (1), par-
ticularly when it is associated with intraabdominal fat deposition
(ie, central obesity) (5). Although it is likely that no single factor
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is responsible for the increased prevalence of moderate obesity,
environmental elements—interacting with predisposing genetic
factors—clearly must be involved (1). Identification of the
acquired causes contributing to an increase in the prevalence of
obesity is necessary to develop public health policy and dietary
and physical activity recommendations that are both comprehen-
sive and effective in reversing the current trend.
The purpose of this review is to explore whether the increased
consumption of dietary fructose might be one of the environmental
factors contributing to the development of obesity and the accom-
panying abnormalities of the insulin resistance syndrome. The
insulin resistance syndrome is a cluster of related variables that
appears to be of major importance in the pathogenesis of coronary
artery disease. The syndrome originally included resistance to
insulin-stimulated glucose uptake, glucose intolerance, hyperinsu-
linemia, hypertension, dyslipidemia characterized by high triacyl-
glycerol concentrations, and low concentrations of HDLs (6). More
recently, the list of abnormalities has been expanded to include cen-
tral obesity (7); small, dense LDLs (8); increased uric acid concen-
trations (9); higher circulating concentrations of plasminogen acti-
vator inhibitor 1 (10); and decreased circulating concentrations of
adiponectin (11). In addition, a link between local adipose steroid
metabolism and the insulin resistance syndrome has been suggested
by reports that the activity of 11-hydroxysteroid dehydrogenase (EC
1.1.1.146) is increased in the adipose tissue of obese humans (12).
Increased expression of this enzyme, specifically in adipose tissue,
was shown recently to induce visceral obesity, insulin-resistant dia-
betes, and hyperlipidemia in a transgenic mouse model (13).
The terms syndrome X, metabolic syndrome, and insulin resist-
ance syndrome have been used in the literature to describe the
observed clustering of metabolic abnormalities. It has been
hypothesized that insulin resistance, which may affect 25% of
middle-aged adults in this country (14), is the common etiologic
factor in the syndrome (6). The macronutrient content of the diet
has been linked to the insulin resistance syndrome. For example,
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FIGURE 1. Annual per capita use of sucrose, high-fructose corn syrup
(HFCS), glucose syrup, dextrose, and other sweeteners (honey, maple
syrup, and molasses) in 1970 and 1997 (19). All of the 0.23 kg HFCS used
in 1970 contained 42% fructose. In 1997, 38% of the HFCS used contained
42% fructose and 62% of the HFCS contained 55% fructose.
FIGURE 2. Annual per capita use of fructose from sucrose and high-
fructose corn syrup (HFCS) and annual per capita use of glucose from
sucrose, HFCS, glucose syrup, and dextrose in 1970 and 1997, calculated
from the disappearance data for added sweeteners (19). The use of both
fructose and glucose increased by 26–27% from 1970 to 1997.
high-fat, particularly high saturated fat, diets induce weight gain,
insulin resistance, and hyperlipidemia in humans and animals
(15–18). In addition to the known effects of dietary fat, dietary
fructose has been shown to produce weight gain and induce
insulin resistance, hyperlipidemia, and hypertension in experi-
mental animals. It is therefore possible that increased consump-
tion of fructose could contribute to weight gain and its accompa-
nying metabolic disturbances in humans.
FRUCTOSE CONSUMPTION
Changes in diet have been studied as contributing factors to the
development of obesity. Along with an increase in total energy
consumption over the past few decades (19), there has been a shift
in the types of nutrients consumed in the American diet. The con-
sumption of fructose has increased, largely because of an
increased consumption of soft drinks and many other beverages
that are high in fructose and because of the consumption of foods
such as breakfast cereals, baked goods, condiments, and prepared
desserts sweetened with sucrose and high-fructose corn syrup
(HFCS). HFCS is produced by the enzymatic isomerization of
dextrose to fructose (20). The commercial use of HFCS began to
increase in the 1970s and, by 1985, HFCS accounted for 35% of
the total amount of sweeteners by dry weight in the food supply
(21). Although HFCS can contain up to 90% fructose (22), most
of the HFCS used in beverages contains 55% fructose.
In a 1993 article, the authors estimated the mean individual con-
sumption of fructose in adolescents and adults to be 40 g/d, the range
being 29–54 g/d (21). Thirteen of the 40 g of dietary fructose is esti-
mated to come from naturally occurring sources of fructose, and 27 g
is estimated to come from added sources of fructose. Young males
(15–18 y of age) reported the highest fructose intakes with a 90th per-
centile intake of fructose from all sources of nearly 100 g/d. However,
these intakes were based on the 1977–1978 US Department of Agri-
culture Nationwide Food Consumption Survey and are likely to seri-
ously underestimate current consumption, because the consumption of
HFCS-sweetened beverages has increased markedly during the inter-
vening time. In addition, at the time that the article by Park and Yetley
(21) was written, the use of crystalline fructose had just been expanded
to the general food supply. To our knowledge, aside from the food dis-
appearance data discussed below, there are no more recent data avail-
able on the amount of fructose currently consumed in the United States.
Food disappearance data serve as indicators of trends in con-
sumption over time (19). As depicted in Figure 1, although the per
capita use of sucrose decreased moderately from 46.4 kg (102 lb)
in 1970 to 30.5 kg (67 lb) in 1997, the per capita use of HFCS
increased from a negligible 0.23 kg (0.5 lb) in 1970 to 28.4 kg
(62.4 lb) in 1997 (19). The use of glucose syrup also increased,
whereas the contribution of other sweeteners—supplied as honey,
molasses, and maple syrup—remained constant at 1% (Figure 1).
The use of glucose and fructose calculated from sweetener disap-
pearance increased in parallel during this time period (Figure 2).
Calculated on a daily basis, the per capita use of added fructose,
obtained by combining the disappearance data for the fructose con-
tained in sucrose and in HFCS, increased by 26%, from 64 g/d in
1970 to 81 g/d in 1997. This represents an average daily energy
intake from added fructose of 1356 kJ (324 kcal). In addition, a
19% increase in fruit and vegetable consumption was observed
between 1982 and 1997 (19). This could lead to a small (2.5 g/d)
increase in naturally occurring fructose in the diet, raising the esti-
mated amount of naturally occurring fructose in the diet to 15–16 g/d
for an average total fructose use of 97 g/d (1624 kJ, or 388 kcal) in
1997. Just two 355-mL (12-oz) soft drinks can supply up to 50 g/
fructose (840 kJ, or 200 kcal) or > 10% of the energy require-
ments for an average-weight woman, without considering any other
dietary sources of fructose. Thus, fructose consumption makes up
a significant proportion of energy intake in the American diet, and
an increased fructose consumption has coincided with an increase
in the prevalence of obesity over the past 2 decades. It therefore is
prudent to ask whether current fructose intakes could contribute to
weight gain and its metabolic sequelae.
FRUCTOSE METABOLISM
The hepatic metabolism of fructose has important effects on
both glucose and lipid metabolism. Absorbed fructose is delivered
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FIGURE 3. Utilization of fructose and glucose in the liver. Hepatic
fructose metabolism begins with phosphorylation by fructokinase (EC
2.7.1.4). Fructose carbon enters the glycolytic pathway at the triose phos-
phate level (dihydroxyacetone phosphate and glyceraldehyde-3-phosphate).
Thus, fructose bypasses the major control point by which glucose carbon
enters glycolysis (phosphofructokinase; EC 2.7.1.11), where glucose
metabolism is limited by feedback inhibition by citrate and ATP. This allows
fructose to serve as an unregulated source of both glycerol-3-phosphate and
acetyl-CoA for hepatic lipogenesis. P, phosphate.
to the liver via the portal vein (23). Fructose is phosphorylated in
the liver by adenosine triphosphate to form fructose-1-phosphate.
The reaction is catalyzed by the enzyme fructokinase (EC 2.7.1.4).
Fructose-1-phosphate is split by aldolase B (EC 4.1.2.13) into
glyceraldehyde and dihydroxyacetone phosphate. Both can be
converted to glyceraldehyde-3-phosphate. Thus, the fructose mol-
ecule is metabolized into 2 triose phosphates that bypass the main
rate-controlling step in glycolysis, 6-phosphofructokinase (EC
2.7.1.11) (Figure 2). In contrast, hepatic glucose metabolism is
limited by the capacity to store glucose as glycogen and, more
importantly, by the inhibition of glycolysis and further glucose
uptake resulting from the effects of citrate and ATP to inhibit
phosphofructokinase (Figure 3). The products of fructose metab-
olism in the glycolytic pathway of the liver are glucose, glycogen,
lactate, and pyruvate. Because fructose uptake by the liver is not
inhibited at the level of phosphofructokinase, fructose consump-
tion results in larger increases of circulating lactate than does con-
sumption of a comparable amount of glucose.
Infusing small amounts of fructose intraportally in dogs appears
to have a catalytic action that increases hepatic glucose uptake (24),
an effect likely to be mediated by hepatic glucokinase. More
recently, a low-dose infusion of fructose has been shown to increase
carbon flux through glycogen synthase (EC 2.4.1.11) and thereby
stimulate glycogen synthesis in humans (25). Low-dose fructose
has also been found to restore the ability of hyperglycemia to reg-
ulate hepatic glucose production (26), and the addition of 7.5 g fruc-
tose to the standard 75 g glucose reduced the glycemic response to
oral-glucose-tolerance tests in adults with type 2 diabetes (27). Thus
small (catalytic) amounts of oral fructose may be beneficial in
improving glycemic control in type 2 diabetes. In addition, fructose
ingestion results in smaller postprandial glycemic excursions com-
pared with glucose and glucose-containing carbohydrates
(starches) that are rapidly absorbed as glucose (28); however,
increased blood fructose concentrations could also contribute to
glycation and diabetic complications.
In contrast with low doses of fructose, when much larger
amounts of fructose are consumed (eg, in sucrose- and HFCS-
sweetened beverages), fructose continues to enter the glycolytic
pathway distal to phosphofructokinase (Figure 3), and hepatic tri-
acylglycerol production is facilitated. Fructose can provide car-
bon atoms for both the glycerol and the acyl portions of acyl-
glycerol molecules (23). Thus, unlike glucose metabolism, in
which the uptake of glucose is negatively regulated at the level of
phosphofructokinase, high concentrations of fructose can serve as
a relatively unregulated source of acetyl-CoA. Indeed, studies in
human subjects have shown that fructose ingestion results in
markedly increased rates of de novo lipogenesis (29, 30), whereas
de novo lipogenesis does not increase in response to eucaloric glu-
cose ingestion (31). Thus, fructose is more lipogenic than is glu-
cose, an effect that might be exacerbated in subjects with existing
hyperlipidemia (32) or insulin resistance or type 2 diabetes (33).
In addition, as discussed below, fructose does not stimulate the
production of 2 key hormones, insulin and leptin, which are
involved in the long-term regulation of energy homeostasis. There-
fore, the decrease in insulin responses to meals and leptin pro-
duction associated with chronic consumption of diets high in fruc-
tose may have deleterious long-term effects on the regulation of
energy intake and body adiposity.
FRUCTOSE, ENERGY INTAKE, AND WEIGHT GAIN
Although energy intake, body weight, and adiposity all increase
in animals consuming high-fructose diets (34–36), considerably
less information is available about humans. The effects of dietary
fructose on weight gain have been reported in 3 studies in human
subjects. Drinking 1150 g soda sweetened with HFCS for 3 wk
resulted in significant increases in ad libitum energy intake and
body weight compared with the same amount of soda with aspar-
tame in male and female subjects (37). Body weight also increased
in a group of 14 middle-aged men, 11 with type 2 diabetes melli-
tus and 3 with type 1 diabetes mellitus, who incorporated 50–60 g
fructose/d into their diets for 24 wk (38). More recently, the effects
of consumption of either sucrose, which consists of 50% fructose,
or an artificial sweetener on ad libitum food intake and body
weight were measured in overweight volunteers. Individuals who
consumed large amounts of sucrose (28% of energy) showed an
increase in energy intake, body weight, fat mass, and blood pres-
sure after the 10-wk intervention (39). Thus, in these limited stud-
ies of fructose or sucrose feeding in humans, the subjects did not
compensate for energy consumed as fructose by reducing ad libi-
tum energy intake from other sources. Although these studies were
not designed to test the effects of fructose on weight gain, the
observation of increased body weight associated with fructose
ingestion is of interest. One explanation for this observation could
be that fructose ingestion did not increase the production of 2
hormones, insulin and leptin, that have key roles in the long-term
regulation of food intake and energy expenditure.
Fructose, unlike glucose, does not stimulate insulin secretion
from pancreatic  cells (40, 41). The lack of stimulation by fruc-
tose is likely due to the low concentrations of the fructose trans-
porter GLUT5 in  cells (42). Insulin is involved in the regulation
of body adiposity via its actions in the central nervous system
(CNS) to inhibit food intake and increase energy expenditure
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(see reviews in references 43 and 44). Briefly, insulin receptors
are localized in CNS areas involved in the control of food intake
and energy homeostasis. Insulin administration into the CNS
inhibits food intake in animals, including nonhuman primates.
Insulin does not enter the brain, but is transported into the CNS
via a saturable receptor-mediated process. Using compartmental
modeling, Kaiyala et al (45) showed that the obesity induced by a
high-fat diet was associated with a 60% reduction of the transport
of insulin into the CNS in dogs. This impairment of central insulin
transport was inversely related to an increase in body weight in
response to high-fat feeding. Specifically, knocking out the insulin
receptor in neurons results in hyperphagia and obesity in mice
(46). Thus, reduced insulin delivery into the CNS or disruption of
the insulin-signaling pathways in the CNS may result in weight
gain and the development of obesity.
As discussed above, there is considerable evidence in support
of the hypothesis that insulin signaling in the CNS lowers food
intake and that insulin functions as a negative feedback signal of
recent energy intake and body adiposity. However, because of the
known anabolic effects of insulin to simulate lipid synthesis and
promote fat storage, there is a widespread belief that insulin
induces weight gain and obesity. This misconception has led to
the promotion of numerous diets suggesting that weight loss can
be achieved by avoiding foods that stimulate insulin secretion.
However, the proponents of such diets do not distinguish between
normal insulin responses to meals in which circulating insulin
concentrations increase and quickly return to fasting concentra-
tions and the chronic hyperinsulinemia secondary to  cell adap-
tation to insulin resistance. Note that reduced glucose-stimulated
insulin secretion has been shown to be prognostic of greater future
weight gain; therefore, increased insulin secretion in response to
meals is unlikely to contribute to weight gain and obesity (47).
A major breakthrough in obesity research came with the cloning
of the defective gene (ob) responsible for hyperphagia and obesity
in an obese diabetic mouse strain (48). The gene is expressed in adi-
pose tissue (49) and its protein product, leptin, functions as a cir-
culating signal from body fat stores to the CNS, where it acts to
limit adiposity by inhibiting food intake and increasing energy
expenditure (50, 51). The effects of insulin and leptin on food intake
appear to share a common signaling pathway via activation of phos-
phatidylinositol-3-kinase (EC 2.7.1.137) (52). The increase in
energy expenditure in rodents may be mediated by activation of the
sympathetic nervous system (53). Leptin administration decreases
food intake and activates the sympathetic nervous system in rhesus
monkeys (54, 55), indicating that leptin has similar biological
effects in primates. In addition, human subjects have been identi-
fied with hyperphagia and marked obesity, resulting from a failure
to produce leptin (56) or from defects in the leptin receptor (57),
and leptin administration decreases the hyperphagia and body adi-
posity resulting from leptin deficiency (58). Relative leptin defi-
ciency, associated with heterozygous leptin gene mutations, was
also shown recently to have a significant biological effect, resulting
in increased body adiposity in humans (59). Decreases in circulat-
ing leptin concentrations correlate with increased sensations of
hunger during prolonged energy restriction in women (60), and lep-
tin administration can reduce appetite in humans (61). Together, the
available evidence strongly suggests an important role for leptin in
the regulation of energy balance in humans (11, 62).
Plasma leptin concentrations are strongly correlated with adi-
posity in rodents (63, 64), nonhuman primates (65), and humans
(64, 66). In humans, plasma leptin decreases after fasting (67) or
energy restriction (68) to a much greater degree than would be
expected from modest changes in body adiposity. However, meal
ingestion does not increase plasma leptin concentrations in short-
term (2–4 h) studies (67), indicating that leptin functions as a
medium- to long-term regulator of energy balance rather than as
a short-term satiety factor such as cholecystokinin (see review in
reference 69). There is a diurnal pattern of plasma leptin concen-
trations in humans, with peak concentrations occurring 6–8 h after
the evening meal (70). The nocturnal increase in leptin is entrained
by meal timing (71) and does not occur if the subjects are fasted
(72). Insulin stimulates leptin gene expression and secretion and
appears to have a major role in the physiologic regulation of lep-
tin production and in determining the magnitude of its diurnal
fluctuation (11). Insulin infusions producing physiologic incre-
ments in plasma insulin have been found to increase circulating
leptin concentrations in humans after several hours (73).
Studies in isolated adipocytes have provided evidence that
increases in glucose transport and metabolism are key steps in
insulin-stimulated leptin expression and secretion in vitro (74). A
blockade of glucose transport or inhibition of glycolysis inhibits
insulin-induced leptin secretion and ob gene expression, and the
activation of the leptin promoter (75) in proportion to the inhibition
in adipocyte glucose utilization. Furthermore, results from these and
other experiments (76) indicate that anaerobic glucose metabolism
does not stimulate leptin secretion, suggesting that glucose oxida-
tion is involved in the effects of insulin on increases in leptin pro-
duction. Glucose metabolism has also been suggested to mediate
the effects of insulin and glucose infusion to increase leptin pro-
duction in humans (77). Thus, increases in insulin-stimulated glu-
cose metabolism after meals would be expected to influence the
diurnal pattern of circulating leptin concentrations (71, 78, 79).
If, as suggested by the in vitro studies, leptin secretion is
dependent on insulin-mediated adipocyte glucose transport and
metabolism, then meals high in carbohydrate, which induce larger
postprandial insulin and glucose excursions, should increase cir-
culating leptin more than would low-carbohydrate meals. When
the ratio of dietary carbohydrate to fat was altered, consumption
of 3 meals with a high proportion of glucose carbohydrate enhanced
insulin secretion, produced larger glucose excursions, and
increased plasma leptin concentrations over 24 h relative to high-
fat, low-carbohydrate meals (80). In another study, when women
were placed on a weight-maintaining regimen, such that energy
intake was adjusted to offset weight loss or weight gain, the sub-
jects needed to be fed significantly more energy (500 ± 125 kJ/d,
or 120 ± 30 kcal/d) when the fat content of the diet was lowered
from 35% to 15% of energy and was replaced with complex car-
bohydrate (66). Poppitt et al (81) compared the effects over 6 mo
of a low-fat, complex-carbohydrate diet; a low-fat, simple-carbo-
hydrate diet; and a control diet in overweight volunteers with ≥ 3
risk factors for metabolic syndrome. Weight loss was greatest in
the low-fat, complex-carbohydrate group. These data suggest that
low-fat, high-carbohydrate feeding may have altered the regulated
level of adiposity, an effect that could be mediated in part by a
long-term increase in leptin production. Conversely, decreased
leptin secretion could contribute to the reported effect of high-fat
diets, ie, weight gain and obesity (82–84).
As previously discussed, fructose, unlike glucose, does not stim-
ulate insulin secretion (41). Although high-carbohydrate meals
stimulate leptin production in humans relative to high-fat meals
(80), if the carbohydrate provided in this study had been fructose
rather than glucose, the results would probably have been different
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because of the dissimilar effects of the 2 sugars on insulin secre-
tion. To compare the effects of glucose and fructose on leptin pro-
duction, plasma leptin concentrations were measured in rhesus
monkeys after intravenous infusion with saline, glucose, or fruc-
tose. Glucose infusion markedly increased plasma glucose and
insulin concentrations and progressively increased plasma leptin
4–8 h into the infusions. In contrast, an intravenous infusion of the
same amount of fructose only modestly increased plasma glucose
and did not stimulate insulin secretion or increase circulating lep-
tin concentrations over an 8-h period (65). To test whether ingested
fructose would produce results similar to those of fructose infu-
sion, 12 women were studied during the randomized consumption
of 3 meals accompanied by fructose-containing beverages on 1 d and
of 3 meals accompanied by glucose-containing beverages on a sep-
arate day. The sweetened beverages supplied 30% of the total
energy provided during the test days. As predicted, the consump-
tion of fructose-containing beverages with the meals resulted in
smaller postprandial glucose and insulin excursions than did the
consumption of glucose-containing beverages. In addition, the con-
sumption of 3 high-fructose meals resulted in lower circulating lep-
tin concentrations over 24 h than did the consumption of 3 high-
glucose meals (85). Furthermore, during consumption of meals
accompanied by glucose beverages, circulating concentrations of
the orexigenic gastric hormone ghrelin (see review in reference 86)
clearly decreased 1–3 h after each meal, whereas ghrelin was much
less suppressed after meals with fructose-containing beverages
(85). Because insulin and leptin, and possibly ghrelin, function as
key signals to the CNS in the long-term regulation of energy bal-
ance (see review in reference 69), the observed decreases in circu-
lating insulin and leptin and increases in ghrelin could lead to
increased energy intake and thereby contribute to weight gain, obe-
sity, and its metabolic consequences during long-term consump-
tion of diets high in energy derived from fructose.
FRUCTOSE CONSUMPTION AND INSULIN RESISTANCE
Diets high in fructose induce insulin resistance in rodents
(87–89) and in dogs (90). For example, Thorburn et al (91) fed rats
a diet containing 35% of energy as fructose for 4 wk and found
reduced insulin sensitivity associated with impaired hepatic insulin
action and whole-body glucose disposal. Both copper-deficient and
copper-replete rats showed adverse changes in glucose metabo-
lism when fed diets containing fructose for 2 wk, whereas rats fed
a comparable amount of starch had no observable effects (92). In
a study in hamsters fed a diet with either a high-fructose or a high-
sucrose carbohydrate source for 2 wk, the rate of glucose disap-
pearance after intravenous glucose administration decreased to a
greater degree after fructose consumption than after consumption
of the sucrose diet, which supplied only 50% as much fructose
(36). Although fructose does not stimulate insulin secretion in the
short term (41), the insulin resistance and obesity induced by long-
term fructose feeding in experimental animals induces compen-
satory hyperinsulinemia. Blakely et al (93) showed significant
increases in fasting serum insulin and fasting serum glucose con-
centrations in rats that consumed 15% of energy as fructose for
15 mo compared with cornstarch-fed rats, even though no differ-
ences in body weight or food intake between the 2 groups were
observed. The effects of dietary fructose on insulin action in
humans are not as well documented. In 1980, Beck-Nielsen et al
(94) investigated whether the reduction in insulin sensitivity
induced by sucrose consumption is related to the glucose or
fructose components of the diet. They found that 7 d of high-
glucose feeding induced no significant changes in insulin sensi-
tivity, whereas high-fructose feeding was accompanied by both
reductions in insulin binding and insulin sensitivity. Other inves-
tigators found that diets containing 15% of energy as fructose pro-
duced undesirable changes in glucose metabolism in both normal
and hyperinsulinemic men (95).
The classic relation between insulin resistance, increased fast-
ing plasma insulin concentrations, and glucose intolerance has
been hypothesized to be mediated by changes in ambient nones-
terified fatty acid concentrations (see review in reference 96).
Elevated nonesterified fatty acid concentrations are one of the
metabolic consequences of a chronic positive energy balance and
increased body adiposity (97). If, as discussed above, fructose
consumption leads to increased body weight as a result of
decreased insulin secretion and reduced leptin production, an
increase in circulating nonesterified fatty acids might follow. The
exposure to increased concentrations of nonesterified fatty acids
may reduce insulin sensitivity by increasing the intramyocellular
lipid content (98). Increased portal delivery of nonesterified fatty
acids, particularly from visceral adipose tissue, could also lead
to impaired carbohydrate metabolism, because elevated portal
nonesterified fatty acid concentrations increase hepatic glucose
production (99, 100). In addition, over time, increased nonester-
ified fatty acid concentrations may have a deleterious effect on
 cell function (101).
An increased supply of nonesterified fatty acids in the liver also
leads to an increase in the production of VLDL triacylglycerol
(102). Fructose consumption has been shown to induce hypertri-
acylglycerolemia (as discussed below). Because insulin resistance
and reduced insulin binding have been reported in hypertriacyl-
glycerolemic persons (103), this may be one mechanism by which
fructose diets promote insulin resistance. Administration of ben-
fluorex, a hypolipidemic agent, reversed the insulin resistance
induced by fructose feeding in rats. The improvement was asso-
ciated with the normalization of triacylglycerol concentrations
(104). However, 3 mo of gemfibrozil administration to 24 persons
with endogenous hypertriacylglycerolemia resulted in marked
decreases in both plasma triacylglycerol and nonesterified fatty
acid concentrations but did not enhance insulin-mediated glucose
disposal and did not lower plasma insulin concentrations (105).
Therefore, the role of triacylglycerol in the development of insulin
resistance remains controversial. On the other hand, postprandial
hypertriacylglycerolemia after fructose ingestion is exacerbated
in subjects with higher fasting insulin concentrations (33), sug-
gesting an interaction between insulin resistance and the lipogenic
effects of fructose (see below).
Another potential mechanism leading to insulin resistance
could involve decreased production of the adipocyte protein,
adiponectin, because reduced circulating concentrations of this
hormone are associated with insulin resistance independently of
body adiposity (11, 106). We are currently investigating the
effects of dietary fructose compared with those of glucose on cir-
culating adiponectin concentrations. Whatever the underlying
mechanism, it is clear that fructose feeding induces insulin resist-
ance and glucose intolerance in rodents. Given the increase in
fructose consumption in the American diet, it is important to
examine whether fructose has similar effects on insulin action
and glucose tolerance in humans, particularly those persons who
are likely to be susceptible to insulin resistance and impaired glu-
cose metabolism.
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FRUCTOSE CONSUMPTION AND LIPIDS
There are numerous studies in which dietary fructose has
been shown to induce hyperlipidemia in rodents (104, 107–109).
Herman et al (107) reported that rats fed a high-fructose diet had
sustained elevations in serum triacylglycerol. Circulating triacyl-
glycerol concentrations rose and remained elevated during the
entire time fructose was fed (100 d) and fell promptly when a
standard chow diet was instituted. The same investigators also
concluded that there was a greater capacity of human liver to
metabolize fructose to lipid compared with glucose because high-
sucrose diets led to elevated serum triacylglycerol concentrations
in humans, whereas the same amount of glucose resulted in lower
concentrations of serum triacylglycerol (107). Fields and Lewis
(110) fed rats copper-adequate or copper-deficient, high-fat diets
with fructose or starch as the sole carbohydrate source. The com-
bination of the high-fat diet with fructose resulted in increased cir-
culating triacylglycerol, and fructose with copper deficiency
resulted in significant increases in blood cholesterol. Hyperlipi-
demia did not develop when starch was combined with a high-fat
diet (110). As previously discussed, the 2 monosaccharides—glu-
cose and fructose—are metabolized differently. Hellerstein (111)
showed that there is little de novo lipogenesis from glucose under
eucaloric conditions in humans. In contrast, Schwarz et al (29, 30,
112) reported 3- to 15-fold increases in fractional de novo lipo-
genesis from fructose above fasting concentrations in obese and
lean subjects (29, 30) and nearly 30% of circulating triacylglyc-
erol palmitate after fructose ingestion resulted from de novo lipo-
genesis derived from fructose (112).
Fructose is the component of sucrose that is considered to be
responsible for some of the adverse effects of this disaccharide on
blood triacylglycerol (113). After extensive work on the metabolic
effects of sucrose at the Beltsville Human Nutrition Research
Center, the investigators focused on fructose specifically. Hall-
frisch et al (114) fed 12 hyperinsulinemic men and 12 male con-
trol subjects diets containing 0%, 7.5%, and 15% of energy from
fructose for 5 wk each in a crossover study. Total plasma choles-
terol and LDL-cholesterol concentrations were higher when the
men consumed 7.5% or 15% of energy as fructose than as starch.
Plasma triacylglycerol concentrations in the hyperinsulinemic
subjects increased as the amount of fructose increased. In 1989
Reiser et al (115) reported results from another 5-wk crossover
study in which 10 hyperinsulinemic and 11 nonhyperinsulinemic
men consumed diets containing 20% of energy as fructose or as
high-amylose cornstarch. Triacylglycerol and cholesterol concen-
trations increased in both groups of subjects when they consumed
fructose, but not cornstarch. Thus, consumption of fructose com-
pared with the same amount of high-amylose cornstarch, produced
undesirable changes in cardiovascular risk factors in both hyper-
insulinemic and nonhyperinsulinemic men.
Not all studies that have evaluated the effects of fructose have
reported increased lipids. In the Turku sugar studies (116), the
effect of chronic consumption of sucrose, xylitol, and fructose was
studied for 2 y in 127 healthy subjects. Substituting fructose or
xylitol for sucrose did not influence plasma cholesterol or tria-
cylglycerol concentrations. Effects on body weight were not
reported. It is important to note, however, that an effect of fructose
alone may have been obscured by comparing its effects with those
of sucrose, which is composed of 50% fructose. In a review arti-
cle on the effects of dietary fructose on lipid metabolism, Hollen-
beck (117) concluded that there is strong evidence that fructose
consumed at 20% of total energy results in an increase in total
and LDL-cholesterol concentrations but added that the effect of
dietary fructose on triacylglycerol concentrations is less clear.
Because most studies reported fasting plasma triacylglycerol con-
centrations, differences in postprandial triacylglycerol excursions
in response to dietary changes may have been missed in some of
the reported studies.
In a recent study in which 17% of energy was consumed as
either crystalline fructose or glucose for 6 wk, both fasting and
postprandial triacylglycerol concentrations were measured (118).
The fructose diet produced significantly higher fasting, postpran-
dial, and daylong plasma triacylglycerol values in older men,
although this effect of fructose was not seen in younger (< 40 y of
age) men or in the older (≥ 40 y of age) women included in the
study. The fructose diet had no significant effects on fasting
plasma cholesterol, HDL cholesterol, or LDL cholesterol in either
men or women. In healthy persons, increases in triacylglycerol
concentrations can decrease over time as a result of metabolic
adaptation, but there does appear to be a subset of individuals who
are particularly sensitive to dietary fructose, including those with
hyperinsulinemia (28). We recently compared the effects of fruc-
tose- and glucose-sweetened beverages (providing 30% of total
energy) consumed with 3 meals over 24 h in 12 young, normal-
weight women without hypertriacylglycerolemia (119). Plasma
triacylglycerol concentrations increased more rapidly and peaked
at higher concentrations after consumption of fructose-containing
than after glucose-containing beverages. Plasma triacylglycerol
concentrations remained elevated after fructose but declined to or
below fasting concentrations several hours after glucose con-
sumption. In addition, fasting triacylglycerol concentrations the
morning after fructose consumption were increased above base-
line concentrations and were elevated compared with fasting tria-
cylglycerol concentrations after glucose consumption. Evidence
exists that this effect of fructose (ie, an increase in postprandial
triacylglycerol concentrations) may be exacerbated in subjects
with hypertriacylglycerolemia (32) or insulin resistance (33).
In a comprehensive review of carbohydrate-induced hypertria-
cylglycerolemia, Parks and Hellerstein (120) reviewed potential
biological mechanisms for the phenomenon in humans. The
authors concluded that elevated triacylglycerol concentrations
observed with increased consumption of dietary carbohydrates
result from elevated triacylglycerol synthesis and, in some per-
sons, from reduced triacylglycerol clearance. The increased syn-
thesis of triacylglycerol results primarily from both increases in
the VLDL particle secretion rate by the liver and in VLDL parti-
cle size. Reductions in triacylglycerol clearance may be due in
part to reductions in lipoprotein lipase (EC 3.1.1.34) activity
(119). Using a fructose-fed Syrian golden hamster animal model,
Taghibiglou et al (121) investigated mechanisms potentially
responsible for the overproduction of VLDL in the insulin-resist-
ant state. They found evidence for enhanced lipoprotein assem-
bly, reduced intracellular apolipoprotein B degradation, and
increased expression of microsomal triacylglycerol transfer pro-
tein. Together, these findings help to explain the increased assem-
bly and secretion of apolipoprotein-B–containing lipoprotein par-
ticles in a fructose-fed, insulin-resistant animal model (121).
In summary, there is an abundance of data in rodents that show
that fructose feeding causes chronic hyperlipidemia. Several short-
term studies in humans have implicated fructose consumption as
a factor promoting unfavorable lipid profiles. Many persons con-
sume sucrose and fructose at amounts in the range of 30% of
energy intake (113). This appears to be particularly true for
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TABLE 1
Studies reporting the effects of fructose or fructose-containing sweeteners on weight gain1
Species Amount fed Length of study Effects on weight Reference
Rats 15% of energy as fructose or 15 mo No differences in body weight or relative food intake 93 
cornstarch
Hamsters 60% fructose or sucrose 2 wk Increased energy intake, weight gain, and adiposity 36 
with fructose
Humans (males and females) 1150 g soda sweetened with 3 wk Increased energy intake and body weight with soda 37
HFCS (80 g fructose) sweetened with HFCS
or artificial sweetener
Humans (middle-aged males) 50–60 g fructose/d 24 wk Increased body weight 38
Humans (overweight males 28% of energy as sucrose or 10 wk Increased energy intake, body weight, and fat mass 39 
and females) artificial sweetener with sucrose intake
1 HFCS, high-fructose corn syrup.
TABLE 2
Studies reporting the effects of fructose or fructose-containing sweeteners on insulin resistance and glucose metabolism
Species Amount fed Length of study Effects on insulin resistance and glucose metabolism Reference
Rats 54% of energy as sucrose or 11–13 wk Increased insulin response to meals and reduced 87
cornstarch insulin sensitivity with sucrose
Rats 35% of energy as fructose or 4 wk Reduced insulin sensitivity with fructose 91 
glucose
Rats 15% of energy as fructose 15 mo Increased fasting serum insulin and fasting serum 93 
glucose with fructose
Rats (copper-replete 62% fructose or starch 2 wk Increased plasma insulin with no reduction of plasma 92 
or -deficient) glucose with fructose
Rats 66% of energy as fructose 2 wk Plasma glucose and insulin responses to oral glucose 132 
load greater in fructose-fed rats
Hamsters 60% fructose or sucrose 2 wk Decrease in glucose disappearance rate with fructose 36 
feeding
Dogs 60% of energy as fructose 20–28 d Fasting insulin concentrations increased and insulin 90
or dextrose sensitivity decreased with fructose
Humans (males and females) 4.18 MJ (1000 extra kcal) as 7 d Reductions in insulin binding and insulin sensitivity 94 
fructose or glucose with fructose
Humans (males with or 0%, 7.5%, and 15% of energy 5 wk each 15% fructose resulted in higher insulin and glucose 95
without hyperinsulinemia) as fructose responses than did the other 2 diets
children (122) and adolescents (123). In the adolescent popula-
tion in the United States, total milk consumption decreased by
36% from 1965 to 1996. During the same time period, soft drink
consumption increased 287% in boys and 224% in girls (124). The
long-term effects of increased consumption of fructose on fasting
and postprandial HDL and LDL cholesterol as well as on circu-
lating triacylglycerol concentrations need further investigation. A
better understanding of whether the initial responses to increased
fructose consumption persist, worsen, or improve with time should
result. In addition, the potential role of fructose in the hypertria-
cyglycerolemia often observed during the consumption of high-
carbohydrate, low-fat diets needs to be clarified.
FRUCTOSE AND HYPERTENSION
Similar to insulin resistance and hyperlipidemia, many pub-
lished experiments have shown that high-fructose diets induce
hypertension in animals, including rodents (125–128) and dogs
(90). In fact, fructose-fed rats are frequently used as a model for
studying the effects of pharmacologic agents for treating hyper-
tension (> 50 studies during the past 5 y). The mechanism of fruc-
tose-induced hypertension is not well understood, but such factors
as uric acid production (113), hyperinsulinemia (129), aldehyde
formation (130), and altered vascular reactivity (131) have been
implicated. Takagawa et al (132) showed that long-term (40 wk)
fructose feeding impaired vascular relaxation in the mesenteric
arteries of male Sprague-Dawley rats. Fructose feeding induced
hypertension in normal-fed and high-salt–fed rats and was asso-
ciated with an increased expression of the angiotensin II type 1
receptor in adipose tissue (133).
Compared with individuals with normal blood pressure, per-
sons with high blood pressure are relatively glucose intolerant (6).
Additionally, lowering blood pressure in hypertensive individuals
does not necessarily reduce the degree of glucose intolerance and
hyperinsulinemia. Two potential explanations for how insulin
resistance and hyperinsulinemia could lead to an increase in blood
pressure are as follows: 1) increases in sympathetic neural out-
flow and plasma catecholamine concentrations associated with
increased plasma insulin concentrations, and 2) insulin action at
the level of the proximal tubule to increase fluid reabsorption (6).
Because hypertension is a well-known comorbidity associated
with obesity, insulin resistance, hyperinsulinemia, and hyperlipi-
demia, it is important to determine the effects of fructose con-
sumption on blood pressure in human subjects.
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TABLE 3
Studies reporting the effects of fructose or fructose-containing sweeteners on lipids1
Species Amount fed Length of study Effects on lipids Reference
Rats 68% fructose 100 d Increased TGs that were reversed when a chow diet 107 
was reintroduced
Rats (copper-replete or Fructose or starch as the sole 4 wk Increased TGs with fructose; increased total 110 
-deficient) carbohydrate source cholesterol with fructose plus copper
Dogs 60% of energy as fructose or 20–28 d Increased fasting TGs with fructose 90 
dextrose
Humans (males with or 0%, 7.5%, or 15% of energy as 5 wk each TGs in hyperinsulinemic men increased as fructose 114
without hyperinsulinemia) fructose increased
Humans (males with or 20% of energy as fructose or 5 wk each TGs increased in both groups with fructose but not 115
without hyperinsulinemia) cornstarch with cornstarch
Humans (males and females Consumed either sucrose, 2 y No differences in plasma cholesterol or TGs 116 
aged 13–55 y) fructose, or xylitol
Humans (males and females) 40 g fat with or without 50 g 10 h Fat plus fructose led to higher postprandial TGs; 32
fructose increased TGs correlated with baseline TGs
Humans (males and females 1 g fat/kg body wt plus 6 h TGs rose more slowly but were higher after fructose 33 
with or without type 2 0.75 g/kg body wt of either than after starch 4–6 h after the meal; increased
diabetes) fructose or starch TGs positively correlated with fasting insulin
Humans (males and females) 17% of energy as either fructose 6 wk Higher fasting and postprandial TGs in older men 118 
or glucose with fructose
Humans (females) 30% of energy as fructose or 24 h Higher postprandial TGs with fructose and higher 85 
glucose with 3 meals fasting TGs the following day
1 TG, triacylglycerol.
TABLE 4
Studies reporting the effects of fructose or fructose-containing sweeteners on blood pressure1
Species Amount fed Length of study Effects on blood pressure Reference
Rats 35% of energy as fructose and 4 wk Increased mean arterial pressure with fructose 104 
35% as starch or 70% starch 
or 59% fat
Rats 5%, 10%, or 20% fructose in ≥1 wk Fructose-induced hypertension with 10% solution by 124 
drinking water end of 1 wk
Rats 66% of energy as fructose with 3 wk Systolic BP increased in fructose-fed rats receiving 132 
or without sodium chloride the high-salt diet
Dogs 60% of energy as fructose or 20–28 d Mean arterial pressure increased with fructose 90 
dextrose
Humans (males with or 0%, 7.5%, or 15% of energy as 5 wk each Systolic BP slightly higher with 0% fructose; no 114 
without hyperinsulinemia) fructose difference in diastolic BP
1 BP, blood pressure.
CONCLUSIONS
The intake of dietary fructose has increased markedly as a
result of the steady increase in added sugars in the American diet
(134). In the past, fructose was considered to be beneficial in the
dietary management of diabetes mellitus and insulin resistance
because fructose ingestion results in smaller postprandial
glycemic and insulin excursions than do glucose and complex car-
bohydrates (28). In light of the information presented here, a cau-
tionary note is warranted. Obesity is a growing epidemic in the
United States. In terms of feedback to the CNS regarding energy
status in peripheral tissues, fructose consumption results in
decreased production and, therefore, decreased signaling to the
CNS from 2 hormones (leptin and insulin) involved in the long-
term regulation of energy homeostasis and body adiposity (11,
69). The same observation applies to dietary fat. Thus, the long-
term consumption of diets high in fat and fructose is likely to lead
to increased energy intake, weight gain, and obesity. The potential
for weight gain from increased fructose consumption may only
represent one aspect of its metabolic consequences (Tables 1–4).
Fructose has been implicated as a contributor to nearly all of
the classic manifestations of the insulin resistance syndrome.
Insulin resistance, impaired glucose tolerance, hyperinsulinemia,
hypertension, and hyperlipidemia are associated with fructose
intake in animal models. The data in humans are less clear, per-
haps in part because the effects of fructose are often compared
with those of sucrose, which is composed of 50% fructose. Other
complicating factors obscuring the effect of dietary fructose on
metabolic indexes include the duration of the studies, the age and
the sex of the subjects tested, and the state in which the measure-
ments are made (ie. fasting or postprandial).
A considerable amount of research needs to be done to more
completely appreciate the effect of fructose in the American diet.
In the meantime, a prudent approach concerning recommendations
for dietary fructose would consider the following 2 points. First,
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added fructose (in the forms of sucrose and HFCS) does not
appear to be the optimal choice as a source of carbohydrate in the
diet. Small amounts of added fructose are probably benign and
may even have some favorable metabolic effects. However, on the
basis of the available data regarding the endocrine and metabolic
effects of consuming large quantities of fructose and the potential
to exacerbate components of the insulin resistance syndrome, it is
preferable to primarily consume dietary carbohydrates in the form
of glucose (free glucose and starch). This may be particularly
important in subjects with existing hyperlipidemia or insulin
resistance who could be more susceptible to the adverse metabolic
effects of fructose. Second, the concerns raised about the addition
of fructose to the diet as sucrose or HFCS should not be extended
to naturally occurring fructose from fruit and vegetables. The con-
sumption of fruit and vegetables should continue to be encouraged
because of the resulting increased intake of fiber, micronutrients,
and antioxidants. In addition, the intake of naturally occurring
fructose is low, 15 g/d, and is unlikely to contribute significantly
to the untoward metabolic consequences associated with the con-
sumption of large amounts of fructose. Certainly, it would be
desirable to have more precise data regarding the current amounts
and patterns of fructose consumption. Unfortunately, to our
knowledge, no accurate data on fructose consumption more recent
than 1977–1978 are available. Although fructose disappearance
data show a clear-cut pattern toward increased consumption of
fructose, more definitive measurements of intake in different pop-
ulations require large-scale surveys. In addition, it is important to
gain a better understanding of the effects and mechanisms of fruc-
tose consumption on metabolic indexes such as insulin sensitivity
and lipid metabolism, including triacylglycerol production.
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interpretation of the quantitative relation between organic anion excre-
tion and dietary UA content only if they were a regular and major com-
ponent of the daily diet. Estimating NEAP as we did for a large num-
ber of preagricultural diets (n = 159), with widely differing plant food
group distribution ratios, gives a more comprehensive picture of the
potential range of preagricultural diet-induced NEAPs, most of which
were computed as decidedly negative values (1).
Nothwithstanding their comments, Remer and Manz accept the
main conclusion of our article. They end by writing, “Taken together,
we also conclude that the average Paleolithic diet principally led to net
base production,” although they suggest that the average NEAP we
reported for 159 diets, 88 mEq/d, might slightly overestimate net
base production because of the presence of noncombustible organic
acids in some food items. We do not necessarily disagree but doubt
that the adjustment is large averaged over 159 different diets, given the
small fraction of natural food items with substantial noncombustible
organic acid content present in the undissociated acid form. Further
limiting the effect of any such noncombustible organic acids, some
fraction of those acids in a food item exist in their dissociated organic
anion form, the amount depending on the acid’s pKa and the pH of the
food. Because such non-bicarbonate-generating organic anions appear
as UAs, they get computed both as part of the bicarbonate yield of the
food and as part of its contribution to the organic anion excretion rate.
Therefore, their effect on the NEAP tends to be cancelled out.
As to meat-eating sweet potato eaters, we concede that odd 2-food
item combinations might yield lower estimates of net base load
than our reported average for preagricultural diets. We reported
several such examples in our paper, even some with net acid loads
(1). It seems unlikely that ancestral hominid diets consisting pre-
dominately of such odd 2-food item combinations were habitually
ingested over millions of years, and therefore it seems unlikely
that they played a dominant role in conditioning the genetic
makeup of humans.
We end by expressing our appreciation to Remer and Manz for
their numerous contributions over many years to our knowledge of
diet effects on NEAP and for their trailblazing efforts in tackling
the problem of computing the NEAP from diet composition. To
the extent that our findings suggest that natural selection likely
has adapted human metabolic machinery and integrated organ
physiology to habitual ingestion of a net base-producing diet, and
not to the modern net acid-producing diet, Remer and Manz merit
a share in the discovery.
Anthony Sebastian
University of California, San Francisco
UCSF/Moffitt General Clinical Research Center
1202 Moffitt Hospital, Box 00126
San Francisco, CA 94143
E-mail: sebastia@gcrc.ucsf.edu
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Metabolic effects of dietary fructose 
Dear Sir:
Elliott et al (1) wrote an interesting article concerning fruc-
tose, weight gain, and the insulin resistance syndrome. In that
review they concluded that an increased consumption of fructose
might be one of the environmental factors contributing to the
development of obesity and the accompanying abnormalities of
the insulin resistance syndrome. It is true that the prevalence of
obesity in the United States and worldwide is increasing, and it
is important to identify the acquired causes contributing to this
increase. However, several lifestyle factors other than an
increased consumption of fructose are much more probable con-
tributors to the development of obesity (eg, a high intake of fat
and minimal physical activity).
Elliott et al described a few mechanisms by which the con-
sumption of dietary fructose might influence glucose metabolism
and insulin resistance. However, they did not address the pro-
longed effects of dietary fructose on glucose metabolism, which
are worthy of review. Type 2 diabetes (or, adult-onset diabetes) is
one of the biggest health problems in the Western world, and it is
suggested to be a consequence of increased energy intake and
decreased physical activity. In persons with type 2 diabetes, the
need for insulin is greater than that able to be produced by the pan-
creas. Therefore, the foods that produce a lower secretion of
insulin (ie, foods that have a low glycemic index) are known to be
beneficial for glucose metabolism. Koivisto and Yki-Jarvinen (2)
studied the effects of dietary fructose (20% of calories as carbo-
hydrate calories; 45–65 g/d for 4 wk) on insulin concentration and
glycated hemoglobin in 10 patients with type 2 diabetes. In that
study, subjects were fed—in a double-blind, randomized crossover
design—a crystalline fructose or isocaloric complex carbohydrate
(control) diet evenly as 4 meals or snacks per day while hospital-
ized. The mean diurnal blood glucose concentration decreased
during both diets, but serum insulin concentration remained
unchanged. Glycated hemoglobin, measured to determine glucose
balance long term, improved only during the fructose diet (9.0%
compared with 8.0%; P < 0.02) (2). In that study, insulin sensitivity
also increased, by 34% (P < 0.05), during the fructose diet but
remained unchanged during the control diet.
Even more long-term effects of a fructose diet on glycemic con-
trol were studied by Osei et al (3). They performed an outpatient
study in 18 patients with type 2 diabetes who consumed either
60 g crystalline fructose/d (n = 9) or their usual meals (n = 9; con-
trol group) for 12 wk. Osei et al reported that both serum glucose
and glycated hemoglobin concentrations progressively decreased
in the group treated with fructose but had a tendency to increase
in the control group during the study. The authors concluded that
a slight improvement in glycemic control and alterations in the
apoprotein composition that favor a decreased risk of coronary
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artery disease may occur with an increased consumption of fruc-
tose (3). The conclusion by Elliott et al that dietary fructose has
only detrimental metabolic and endocrine effects is somewhat
misleading. However, Elliott et al do suggest that much more
research is needed to fully understand the metabolic effects of
dietary fructose, particularly in humans.
Tommi J Vasankari
Department of Physiology
University of Turku
Kiinamyllynkatu 10
20520 Turku
Finland
E-mail: tommi.vasankari@vierumaki.fi
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Reply to TJ Vasankari 
Dear Sir:
We agree with Vasankari that dietary fat and inactivity are likely
environmental factors contributing to the marked worldwide
increase in the prevalence of obesity, and this was noted in our
review on the metabolic effects of fructose (1). However, we
believe that an increase in fructose consumption also deserves
attention as a potential third factor contributing to the escalation of
obesity. Because we are not aware of quantitative data regarding
the relative contributions of the 3 factors, we consider it prema-
ture to conclude that dietary fat and reduced physical activity are
“much more probable contributors” to the obesity epidemic. As
we and Bray (2) have pointed out, fructose consumption has
increased concurrently with the obesity epidemic. Furthermore,
because fructose—similarly to dietary fat—does not stimulate
insulin secretion, leads to decreased leptin production, and does
not suppress the orexigenic gastric hormone ghrelin (3), the lack
of effects of long-term fructose consumption on these endocrine
systems involved in the regulation of energy homeostasis could
lead to increased energy intake, weight gain, and obesity. We there-
fore regard increased fructose consumption to be a likely contrib-
utor to the increased prevalence of obesity in the past 2–3 decades.
Vasankari discusses the inclusion of fructose in the diets of
patients with diabetes because of its low glycemic index. In our
review we briefly addressed this topic and also cited evidence
that the consumption of small catalytic amounts of fructose
increases hepatic glucose uptake and reduces glucose excur-
sions after treatment with oral glucose in subjects with type 2
diabetes (1). Thus, we agree that modest amounts of dietary fruc-
tose may be beneficial in the dietary management of diabetes.
Although we intentionally did not provide an in-depth discus-
sion of or cite additional literature on studies of fructose con-
sumption in diabetes, we believe that certain issues should be
considered before high-fructose diets are recommended for dia-
betic patients. First, when large amounts of fructose are rapidly
consumed, a sufficient amount of fructose may escape hepatic
uptake to significantly elevate systemic circulating fructose
concentrations. Protein fructosylation could contribute to dia-
betic complications (4), particularly because fructose is a major
product of the polyol-sorbitol pathway and because tissue fruc-
tose accumulation has been implicated in diabetic neuropathy
and other complications of diabetes. It was reported that con-
sumption of a high-fructose diet increases both the formation
of cataracts and of oxidative byproducts in the kidneys of strep-
tozotocin-diabetic rats (5). In nondiabetic rats, fructose con-
sumption for 1 y led to increased glycation (fructosamine and
glycated hemoglobin) and markers of lipid peroxidation and
aging when compared with animals that consumed glucose (6).
The effect of dietary fructose on glycation and oxidation-related
products deserves further investigation, and it is important to
determine whether increased glycation and oxidation occur in
humans consuming high amounts of dietary fructose.
In addition, although not all studies have shown an adverse
effect of fructose consumption on lipids, several studies (7–9),
including our own (3), showed that—compared with glucose—
fructose increases postprandial triacylglycerol. Although this
effect is likely to be highly dependent on the amount of fructose
consumed, evidence exists that fructose-induced hypertriglyc-
eridemia is magnified in subjects with insulin resistance (10) or
hypertriglyceridemia (6, 11). Therefore, caution should be exer-
cised when recommending diets high in fructose to patients with
the metabolic syndrome or type 2 diabetes. Furthermore, in pre-
liminary studies, we found that overweight women with normal
fasting triacylglycerol concentrations who consumed 25% of
energy from fructose-sweetened beverages for 10 wk had
markedly increased postprandial triacylglycerol concentrations
(compared with a baseline diet high in complex carbohydrate) and
significantly elevated concentrations of atherogenic apolipopro-
tein B (12). In contrast, postprandial triacylglycerol and
apolipoprotein B concentrations did not increase in subjects who
consumed 25% of energy as glucose, which induced larger post-
prandial circulating glucose and insulin excursions than did the
consumption of complex carbohydrate or fructose. Thus, the con-
sumption of glucose-sweetened beverages—which have a high
glycemic index—does not result in adverse changes in the post-
prandial lipid profile.
In summary, the effects of fructose on postprandial triacylglycerol
and apolipoprotein B concentrations suggest that long-term consump-
tion of high amounts of fructose could contribute to the risk of cardio-
vascular disease. As indicated by some studies, this effect is likely to
be exacerbated in subjects with preexisting metabolic disease. Finally,
as discussed above, the lack of effects on endocrine systems involved
in body weight regulation suggests that the long-term consumption of
diets high in fructose may lead to weight gain, obesity, and the devel-
opment of type 2 diabetes. Clearly, much additional research is needed
to more fully understand the metabolic effects of high-fructose diets,
particularly in subjects at risk of metabolic diseases, ie, obese, insulin-
resistant, or hyperlipidemic persons. Limiting fructose consumption
may be a desirable objective in the management of obesity and hyper-
lipidemia in individual persons and in the prevention of weight gain
and its metabolic consequences at the population level.
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Erratum
Francois CA, Connor SL, Bolewicz LC, Connor WE. Supplementing lactating women with flaxseed oil does not increase
docosahexaenoic acid in their milk. Am J Clin Nutr 2003;77:226–33.
In Table 1 on page 227, the values for fatty acids 18:1n9 and 20:1n9 were interchanged. The value for 18:1n9 should
read 20.5% by wt of total fatty acids, and the value for 20:1n9 should read 0.0% by wt of total fatty acids.
